Beamr video compression achieves up to 50% improvement for AVs
Investing.com -- Monogram Technologies (NASDAQ:MGRM) stock soared 60% after Zimmer Biomet (NYSE:ZBH) announced it will acquire the orthopedic robotics company in a deal valued at approximately $177 million in equity value.
Under the terms of the agreement, Zimmer Biomet will pay $4.04 per share in cash for all outstanding Monogram shares. Additionally, Monogram stockholders will receive a non-tradeable contingent value right (CVR) that could provide up to $12.37 per share if certain product development, regulatory and revenue milestones are achieved through 2030.
The acquisition aims to expand Zimmer Biomet’s ROSA Robotics platform with Monogram’s semi- and fully autonomous robotic technologies. Monogram recently received FDA 510(k) clearance in March 2025 for its CT-based, semi-autonomous, AI-navigated total knee arthroplasty robotic technology, which is expected to be commercialized with Zimmer Biomet implants in early 2027.
"Monogram’s technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation," said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet.
The transaction is expected to be neutral to Zimmer Biomet’s adjusted earnings per share from 2025 through 2027 and accretive thereafter. The company anticipates the acquisition will contribute to revenue growth beginning in 2027 and generate high-single digit return on invested capital by year five.
Both companies’ boards have unanimously approved the deal, which is subject to regulatory approvals, Monogram stockholder approval, and other customary closing conditions. The merger is expected to close later this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.